[Quality of life and problems posed by hypoglycemia in type 2 diabetes mellitus during oral hypoglycemic therapy].
Quality of life characteristics, hypoglycemic episodes and patients' attitude toward them were estimated in the patients with type 2 diabetes mellitus based on the modern recommendations for the patient-oriented treatment with metformin in combination with sulfonylurea derivatives (M+S) therapy, traditional approach, n = 83) and metformin in combination with vildagliptin (M+V therapy, innovative approach, n = 111). M+V therapy ensured a higher quality of life than M+S therapy based on all SF-36 scales. Quality of life parameters corresponded to population norms in most patients given M+V therapy and only in 52% of those treated with M+S. The frequency of hypoglycemic episodes, related concerns, and other problems associated with this condition were less apparent in case of M+V therapy. Transition from M+S to M+V therapy resulted in the improvement of quality of life and reduction in the frequency of hypoglycemia. Quality of life did not change after transition to M+S therapy while the frequency of hypoglycemia and the number of related problems increased. HbA1c levels were similar in both groups (0.8% difference). According to patients' reports M+V therapy is more efficient than M+S; these data allow to comprehensively evaluate the efficacy of therapy and monitor the health state of diabetic patients in the course of treatment.